Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (3633)	11/22/2002 4:36:13 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 10345

Elan Completes Sale of Abelcet DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 22, 2002--Elan Corporation, plc (NYSE: ELN) ("Elan") today announced the completion of the sale of its United States, Canadian and any Japanese rights to Abelcet(TM) (injectible amphotericin B lipid formulation), and certain related assets to Enzon, Inc. (NASDAQ: ENZN). Elan has received a net cash payment of $360 million from Enzon representing the total consideration, after agreed price adjustments, for the transaction that was previously announced on October 2, 2002. The entire proceeds from the sale will form part of Elan's targeted proceeds from the divestment of assets as outlined in its recovery plan. Elan is focused on the discovery, development, manufacturing, selling and marketing of novel therapeutic products in neurology, pain management and autoimmune diseases. Elan shares trade on the New York, London and Dublin Stock Exchanges. (snip)